Current Diabetes Reports

, Volume 9, Issue 1, pp 1–3 | Cite as

Inhibition of the RAS and prevention of diabetes and CVD: Mechanistic insights and lessons learned from clinical trials

Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H–37H.PubMedCrossRefGoogle Scholar
  2. 2.
    Fox K, Ferrari R, Yusuf S, Borer JS: Should angiotensin-converting enzyme inhibitors be used to improve outcome in patients with coronary artery disease and “preserved” left ventricular function? Eur Heart J 2006, 27:2154–2157.PubMedCrossRefGoogle Scholar
  3. 3.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  4. 4.
    Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782–788.PubMedCrossRefGoogle Scholar
  5. 5.
    Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group [no authors listed]. Circulation 1998, 97:2202–2212.Google Scholar
  6. 6.
    Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450–1456.PubMedCrossRefGoogle Scholar
  7. 7.
    Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.PubMedCrossRefGoogle Scholar
  8. 8.
    Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.PubMedCrossRefGoogle Scholar
  9. 9.
    Farag A, Karam J, Nicasio J, McFarlane SI: Prevention of type 2 diabetes: an update. Curr Diab Rep 2007, 7:200–207.PubMedCrossRefGoogle Scholar
  10. 10.
    Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  11. 11.
    Bosch J, Yusuf S, Gerstein HC, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551–1562.PubMedCrossRefGoogle Scholar
  12. 12.
    Califf RM, Boolell M, Haffner SM, et al.: Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008, 156:623–632.PubMedCrossRefGoogle Scholar
  13. 13.
    McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.PubMedCrossRefGoogle Scholar
  14. 14.
    Kudoh A, Matsuki A: Effects of angiotensin-converting enzyme inhibitors on glucose uptake. Hypertension 2000, 36:239–244.PubMedCrossRefGoogle Scholar
  15. 15.
    Tikellis C, Wookey PJ, Candido R, et al.: Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004, 53:989–997.PubMedCrossRefGoogle Scholar
  16. 16.
    Suzuki K, Nakagawa O, Aizawa Y: Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens 2008, 30:309–314.PubMedCrossRefGoogle Scholar
  17. 17.
    Yusuf S, Diener HC, Sacco RL, et al.: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225–1237.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Division of Endocrinology, Department of MedicineState University of New York-Downstate Medical Center and Kings County HospitalBrooklynUSA

Personalised recommendations